Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study.

被引：0

作者：

Fernandez Montes, Ana

Ros, Javier

Grana, Begona

Garcia-Alfonso, Pilar

Brozos, Elena

Melian, Marcos

Jimenez-Gordo, Ana M.

Martinez de Castro, Eva

Busquier, Isabel

Gallego, Javier

Gravalos, Cristina

Covela, Marta

Ruiz-Casado, Ana

Gonzalez Flores, Encarnacion

Safont, Mariajose

Maria Cano, Juana

Alonso Lopez, Carmen

Gomez-Reina, Maria Jose

Donnay, Olga

Aranda, Enrique

机构：

[1] Complexo Hosp Univ Ourense CHUO, Dept Med Oncol, Orense, Spain

[2] Vall dHebron Univ Hosp CHUO, Dept Med Oncol, Barcelona, Spain

[3] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[4] A Coruna Univ Hosp, Inst Invest Biomed INIBIC, La Coruna, Spain

[5] Hosp Univ Gregorio Maranon, Dept Med Oncol, Madrid, Spain

[6] CHUS, Santiago De Compostela, Spain

[7] Inst Valenciano Oncol, Valencia, Spain

[8] Hosp Univ Infanta Sofia, Dept Med Oncol, San Sebastian Los Reyes, Spain

[9] Univ Hosp Marques de Valdecilla, Dept Med Oncol, IDIVAL, Santander, Spain

[10] Hosp Prov Castellon, Valencia, Spain

[11] Hosp Gen Univ Elche, Alicante, Spain

[12] Hosp Univ 12 Octubre, Madrid, Spain

[13] Hosp Univ Lucas Augusti HULA, Lugo, Spain

[14] Hosp Univ Puerta de Hierro, Dept Med Oncol, Madrid, Spain

[15] Hosp Virgen de las Nieves, Granada, Spain

[16] Hosp Gen Valencia, Valencia, Spain

[17] Hosp Gen Univ Ciudad Real, Ciudad Real, Spain

[18] Complejo Hosp Univ Albacete, Albacete, Spain

[19] Hosp Univ Nuestra Senora de Valme, Seville, Spain

[20] Hosp Univ Princesa, Madrid, Spain

[21] Hosp Univ Reina Sofia, Cordoba, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

126

引用

页码：126 / 126

页数：1

共 50 条

[1] Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer
Huijberts, Sanne C. F. A.
van Geel, Robin M. J. M.
Bernards, Rene
Beijnen, Jos H.
Steeghs, Neeltje
FUTURE ONCOLOGY, 2020, 16 (06) : 161 - 174
[2] BREAKWATER safety lead-in (SLI): Encorafenib (E) plus cetuximab (C) plus chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).
Kopetz, Scott
Yoshino, Takayuki
Kim, Tae Won
Yaeger, Rona
Desai, Jayesh
Wasan, Harpreet Singh
Van Cutsem, Eric
Ciardiello, Fortunato
Maughan, Tim
Eng, Cathy
Tie, Jeanne
Elez, Elena
Lonardi, Sara
Zhang, Xiaosong
Chung, Chin-Hee
Usari, Tiziana
Nicholz, Tim
Murphy, Danielle A.
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 119 - 119
[3] Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer
Morris, Van K.
Parseghian, Christine Megerdichian
Escano, Michelle
Johnson, Benny
Raghav, Kanwal Pratap Singh
Dasari, Arvind
Huey, Ryan
Overman, Michael J.
Willis, Jason
Lee, Michael Sangmin
Wolff, Robert A.
Kee, Bryan K.
Shen, John Paul Y. C.
Morelli, Maria Pia
Tam, Alda
Foo, Wai Chin
Xiao, Lianchun
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[4] BREAKWATER safety lead-in (SLI): Encorafenib (E) plus cetuximab (C) plus chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)
Tabernero, J.
Yoshino, T.
Kim, T. W.
Yaeger, R.
Desai, J.
Wasan, H. S.
Van Cutsem, E.
Ciardiello, F.
Maughan, T.
Eng, C.
Tie, J.
Fernandez, M. E. Elez
Lonardi, S.
Zhang, X.
Chavira, R.
Usari, T.
Hahn, E.
Kopetz, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1392 - S1393
[5] Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), BRAFV600E metastatic colorectal cancer.
Morris, Van K.
Parseghian, Christine Megerdichian
Escano, Michelle
Johnson, Benny
Raghav, Kanwal Pratap Singh
Dasari, Arvind
Huey, Ryan
Overman, Michael J.
Willis, Jason
Lee, Michael Sangmin
Wolff, Robert A.
Kee, Bryan K.
Le, Phat
Margain, Cori
Gallup, Dave
Tam, Alda
Foo, Wai Chin
Xiao, Lianchun
Yun, Kyuson
Kopetz, Scott
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Advances in the therapy of BRAFV600E metastatic colorectal cancer
Jin, Zhaohui
Sinicrope, Frank A.
EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (09) : 823 - 829
[7] Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
Sanne C. F. A. Huijberts
Mirjam C. Boelens
Rene Bernards
Frans L. Opdam
British Journal of Cancer, 2021, 124 : 176 - 182
[8] Encorafenib plus cetuximab in patients with BRAFV600E-mutated metastatic colorectal cancer - Polish multicenter experience
Radecka, Barbara
ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (04): : 308 - 308
[9] Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
Hong, David S.
Morris, Van K.
El Osta, Badi
Sorokin, Alexey V.
Janku, Filip
Fu, Siqing
Overman, Michael J.
Piha-Paul, Sarina
Subbiah, Vivek
Kee, Bryan
Tsimberidou, Apostolia M.
Fogelman, David
Bellido, Jorge
Shureiqi, Imad
Huang, Helen
Atkins, Johnique
Tarcic, Gabi
Sommer, Nicolas
Lanman, Richard
Meric-Bernstam, Funda
Kopetz, Scott
CANCER DISCOVERY, 2016, 6 (12) : 1352 - 1365
[10] Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program
Kotani, Daisuke
Takashima, Atsuo
Kato, Takeshi
Satoh, Taroh
Masuishi, Toshiki
Komatsu, Yoshito
Shiozawa, Manabu
Esaki, Taito
Izawa, Naoki
Takeuchi, Shinji
Bando, Hideaki
Iwasa, Satoru
Hasegawa, Hiroko
Yamaguchi, Toshifumi
Taniguchi, Hiroya
Ushida, Yasunori
Oizaki, Toshiya
Inoue, Chiaki
Yoshino, Takayuki
CLINICAL COLORECTAL CANCER, 2024, 23 (02) : 174 - 182.e6

← 1 2 3 4 5 →